ABT

Abbott Laboratories

Abbott Laboratories is a health care company that manufactures medical devices, blood glucose monitoring kits, nutritional healthcare products, diagnostic products and equipment, and branded generic drugs.

Abbott Laboratories (ABT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (D+). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B+
Factor Score 3.5 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
D+
Factor Score 1.8 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 40.5
EV / EBITDA 18.8
Rev Growth YoY 14.5%
Gross Margin 57.2%
Price Return 3M -1.1%
Price Return 12M -13.7%
Catalyst Signal +0.07
Market Cap $188.0B
TTM Revenue $48.2B
Price / Sales 3.9
ROE 9.1%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 C+ (2.7) C- (1.9) B+ (3.5) B (3.2) D+ (1.8) C+ (2.6)
2026-11-09 C+ (2.6) C- (1.9) B+ (3.5) B- (3.1) C+ (2.8) C+ (2.8)
2026-11-04 C+ (2.7) C- (1.9) B+ (3.8) B- (2.9) C+ (2.7) C+ (2.8)
2026-11-03 C+ (2.7) C- (1.9) B+ (3.7) C+ (2.8) B- (3.0) C+ (2.8)
2026-11-02 C+ (2.7) C- (1.9) B+ (3.7) C+ (2.7) B- (3.0) C+ (2.8)
Page 1 of 13
…